<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Brain and brawn Parallels in oxidative strength</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MA</roleName><forename type="first">P</forename><forename type="middle">I</forename><surname>Moreira</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">;</forename><forename type="middle">K</forename><surname>Honda</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">;</forename><forename type="middle">X</forename><surname>Zhu</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">;</forename><forename type="middle">A</forename><surname>Nunomura</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">;</forename><forename type="middle">G</forename><surname>Casadesus</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
						</author>
						<author role="corresp">
							<persName><roleName>PhD</roleName><forename type="first">George</forename><surname>Perry</surname></persName>
							<email>george.perry@case.edu</email>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Center for Neuroscience and Cell Biology of Coimbra (P.I.M.)</orgName>
								<orgName type="institution">Case Western Reserve University</orgName>
								<address>
									<settlement>Cleveland</settlement>
									<region>OH</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution">University of Coimbra</orgName>
								<address>
									<settlement>Coimbra</settlement>
									<country key="PT">Portugal</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Department of Psychiatry and Neurology (A.N.)</orgName>
								<orgName type="institution">Asahikawa Medical College</orgName>
								<address>
									<settlement>Asahikawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Philip Morris USA Inc</orgName>
								<orgName type="institution" key="instit2">Philip Morris International</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Case Western Reserve University</orgName>
								<address>
									<addrLine>2085 Adelbert Road</addrLine>
									<postCode>44106</postCode>
									<settlement>Cleveland</settlement>
									<region>OH</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Brain and brawn Parallels in oxidative strength</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">A61FB8FA5E207A29B63C24F6339EED12</idno>
					<note type="submission">Received June 22, 2005. Accepted in final form October 14, 2005.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Neuronal oxidative stress occurs early in the progression of Alzheimer disease (AD), significantly before the development of the pathologic hallmarks, neurofibrillary tangles, and senile plaques. Study of Down syndrome, cases with autosomal dominant mutation, and sporadic AD all suggest amyloid-␤ deposition and hyperphosphorylated function as compensatory responses and downstream adaptations to ensure that neuronal cells do not succumb to oxidative damage. Amyloid-␤ and hyperphosphorylation also define vulnerable muscle cells in sporadic inclusion-body myositis (s-IBM). The role of the structural changes of s-IBM, as in AD, remains to be determined but may mark a critical response yielding a novel balance in oxidant homeostasis.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Alzheimer disease (AD) is a common and complex neurodegenerative disorder that affects approximately 15 million people worldwide. <ref type="bibr" target="#b0">1</ref> Aging is the major risk factor for a disease that coexists with other causes of cognitive decline, particularly diffuse Lewy body disease and Pick diseases as well as frontal temporal dementia that can masquerade as AD. The neuropathological hallmarks of AD are intracellular neurofibrillary tangles (NFT), containing mainly polymerized and hyperphosphorylated protein, and the accumulation of extracellular amyloid plaques containing mainly amyloid-␤ (A␤). AD is devastating, and, despite great strides in recent years, still puzzling in its causes and mechanisms. Although the etiology of AD remains largely unclear, there is accumulating evidence that oxidative stress plays an important role in the disease pathophysiology. However, intracellular oxidative balance is tightly regulated and, therefore, the activation of multiple signaling pathways and the upregulation of compensatory mechanisms would be expected to occur in neurons from AD patients.</p><p>Complex pathophysiology involving formation of lesions that are similar to those of AD but found in muscle characterizes sporadic inclusion-body myositis (s-IBM), an age-dependent degenerative condition. Although neurodegenerative conditions show distinct pathologic profiles from AD, s-IBM shows almost complete overlap with those displayed with AD, prion, <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref> and Parkinson 5 diseases. Finding the changes of AD in muscle cells makes one consider what is shared between neurons and muscle. The accessibility of muscle cells to culture offers the opportunity to manipulate cells through genetic or pharmacologic interventions, techniques lacking in AD research. These aspects are discussed in great length in the accompanying articles. We review the oxidative abnormalities and compensations that define AD that have bearing on both disease conditions.</p><p>Oxidative stress is a prominent event in the development of Alzheimer disease. Oxidative status was initially understood as oxidative stress (i.e., the breaching of oxidant defenses with consequent cellular detrimental effect). <ref type="bibr" target="#b5">6</ref> According to this definition, detection of damage resulting from reactive oxygen or nitrogen species indicates the existence of oxidative stress. However, living systems dynamically regulate their defense mechanisms in response to oxidative stress. Therefore, increases in oxidative damage do not indicate that the cell is succumbing to oxidative stress but indicates an increase in defenses sufficient to compensate for the increased flux of reactive species responsible for the damage. This concept is critically outlined by evidence suggesting that cells that fail to compensate for oxidative imbalance enter into apoptosis, which in turn leads to death within hours. <ref type="bibr" target="#b6">7</ref> Following this point of view, we suggest that cells can only experience oxidative stress for short periods of time without rapidly dying. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b8">9</ref> In chronic degenerative disorders, such as AD, the cells experiencing increased oxidative damage develop compensatory responses aimed to avoid, or at least reduce, cellular damage.</p><p>Oxidative damage is a prominent and early feature of vulnerable neurons in AD. <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11</ref> Oxidative modification of macromolecules has been described in association with the susceptible neurons of AD in numerous studies. Such modifications include advanced glycation end products, <ref type="bibr" target="#b11">12</ref> nitration, <ref type="bibr" target="#b10">11</ref> lipid peroxidation adduction products, <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14</ref> carbonylmodified neurofilament protein, and free carbonyls, as well as glycation and glycoxidation products. <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref> Levels of these markers are initially elevated following some unknown triggering neuronal event, but these levels soon decrease as the disease progresses to advanced AD. <ref type="bibr" target="#b17">18</ref> Together these findings suggest that increased oxidative damage is not the terminal sequelae of the disease but instead plays an initial role. They also suggest that damage does not mark further destruction by reactive species and is instead marked by a broad array of increased cellular defenses. <ref type="bibr" target="#b17">18</ref> It can be argued that in AD these defenses are responsible for the reduction of damage if we view AD in isolation. However, when seen in the context of other conditions where reactive oxygen and nitrogen species are involved and damage is either limited or absent, such as Parkinson disease (PD), this leads us to consider whether oxidative damage noted in AD may be better thought of as homeostatic, such that oxidative damage could initiate signal transduction pathways to manipulate cellular responses to stress, which are characterized by increased levels of reactive oxygen and nitrogen species. <ref type="bibr" target="#b17">18</ref> Mitochondria. Extensive evidence indicates that cerebral oxidative metabolism is reduced in AD, <ref type="bibr" target="#b18">19</ref> placing mitochondria as a key player in this scenario. <ref type="bibr" target="#b19">20</ref> Mitochondria are essential organelles for neuronal function because, differing from muscle, the limited glycolytic capacity of these cells makes them highly dependent on aerobic oxidative phosphorylation for their energetic needs. However, oxidative phosphorylation is a major source of endogenous toxic free radicals, including hydrogen peroxide (H 2 O 2 ), hydroxyl (OH⅐) and superoxide (O2 -⅐) that are products of normal cellular respiration. <ref type="bibr" target="#b20">21</ref> Reactive species generated by mitochondria have several cellular targets including mitochondrial components themselves (lipids, proteins, and DNA). The lack of histones in mitochondrial DNA (mtDNA) and diminished capacity for DNA repair render mitochondria an easy target to oxidative stress events. By releasing high levels of H 2 O 2 , dysfunctional mitochondria promote the interaction between redox metals and oxidative response elements. <ref type="bibr" target="#b21">22</ref> The role of mitochondria in AD was studied in our laboratory using in situ hybridization to mitochondrial DNA, immunocytochemistry of cytochrome oxidase, and morphometry of electron micrographs of biopsy specimens to determine whether there were mitochondrial abnormalities in AD. <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b22">23</ref> We found that the neurons show-ing increased oxidative damage in AD possess also a striking and significant increase in mtDNA and cytochrome oxidase. Surprisingly, much of the mtDNA and cytochrome oxidase is found in the neuronal cytoplasm and in the case of mtDNA, the vacuoles associated with lipofuscin, whereas morphometric analysis showed that mitochondria are significantly reduced in AD. Mitochondrial abnormalities such as accumulation of deleted mtDNA also characterize s-IBM. <ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref> We also observed an overall reduction in microtubules in AD compared to controls. <ref type="bibr" target="#b27">28</ref> Altogether these data indicate that the abnormal mitochondrial turnover, as indicated by increased perikaryal mtDNA and mitochondrial protein accumulation in the face of reduced numbers of mitochondria, could be due to a defective microtubule metabolism resulting in deficient mitochondrial transport in the axon. This may, in turn, set up a pathologic cascade of events in the perikaryal mitochondria. It would be intriguing to examine microtubules in s-IBM because abnormalities define the condition.</p><p>Accumulating evidence indicate that hemeoxygenase-1 (HO-1) is induced in AD brains. <ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref> HO-1 catalyzes the conversion of heme to biliverdin and iron. Biliverdin, in turn, is reduced to bilirubin, an antioxidant. Because HO-1 is induced in proportion to the level of heme, <ref type="bibr" target="#b31">32</ref> the induction of HO-1 suggests that there may be abnormal turnover of heme in AD. This idea is consistent with the mitochondrial abnormalities associated to AD because it is well known that many heme-containing enzymes are found in mitochondria. As previously discussed, our ultrastructural studies concerning mitochondria suggest a high rate of mitochondrial turnover and redox activity in the residual body of lipofuscin <ref type="bibr" target="#b19">20</ref> with lysosomes as the probable sources of heme. In turn, the increase in heme induces synthesis of more HO-1, suggesting that mitochondrial turnover promotes oxidative stress via increase of redox-active iron. <ref type="bibr" target="#b32">33</ref> Furthermore, we observed that oxidized nucleic acids are commonly observed in the cytoplasm of the neurons that are particularly vulnerable to degeneration in sporadic <ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b34">35</ref> and familial <ref type="bibr" target="#b35">36</ref> AD, which suggest a link between oxidative stress and not only age-associated degenerative diseases but also neurodegeneration linked to genetic factors. 8-hydroxyguanosine (8OHG), a marker of nucleic acids oxidation, is likely to form at the site of ⅐OH production, a process dependent on redox-active metalcatalyzed reduction of H 2 O 2 together with cellular reductants such as ascorbate or O 2 -. Interestingly, the levels of 8OHG are inversely related to the extent of A␤ deposits being this oxidative marker is found physically distant from the A␤ deposits <ref type="bibr" target="#b33">34</ref> suggesting a complex interplay between A␤ and redox metal activity that may be critical to metal dynamics within the neuronal cytoplasm. A possible key element to these dynamics is mitochondria.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cellular compensatory responses.</head><p>Oxidative modification and response are controlled events that play critical roles in response to oxidative stress. This view is supported by data comparing AD with normal aging, where we documented the same profile of damage, albeit with lower levels. <ref type="bibr" target="#b33">34</ref> AD differs from other neurodegenerative diseases in that it shows exponential prevalence with aging. This makes AD a part of the normal aging process, which encompasses additional specific pathologic mechanisms and suggests that many of the oxidative modifications may not only result from aging but also play a role in balancing systems underlying the metabolic abnormalities present in AD. Support for this idea comes from the analysis of lipid peroxidative modification of and neurofilament heavy subunit (NFH), two of the components of neurofibrillary tangles. <ref type="bibr" target="#b36">37</ref> Recently, Wataya et al. <ref type="bibr" target="#b37">38</ref> suggested that NFTs are antioxidants because both and neurofilament protein appear uniquely adapted to oxidative attack due to their high content of lysine-serine-proline domains. Exposure of these domains on the surface is affected by extensive phosphorylation of serine residues. <ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b38">39</ref> In AD, both and NFH are found as adducts of HNE and the modifications are controlled by phosphorylation. <ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b37">38</ref> While NFH is modified by HNE at similar levels in AD and controls (Perry and Smith, unpublished data), normal brains present only small modifications. <ref type="bibr" target="#b29">30</ref> modification by HNE greatly increases its ability to form filaments, in vitro <ref type="bibr" target="#b39">40</ref> and in cells, <ref type="bibr" target="#b40">41</ref> similar to those found in NFT. The link to phosphorylation and the known similarity of oxidative imbalance to induction of the MAP kinase pathway <ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref> suggest that lipid peroxidation modification of is regulated by signal transduction pathways. Studies performed with rodents show that NFH-HNE levels do not increase with aging or movement of NFH to terminals, suggesting that levels of adduction are further regulated by removal or reversal of NFH-HNE adducts. <ref type="bibr" target="#b37">38</ref> These data indicate these processes may play a physiologic role in axons, possibly in protecting axonal components by scavenging toxic aldehydes formed during normal metabolism. This would be essential for axons, which cannot turn over and replace proteins as rapidly as cell bodies.</p><p>Transfection studies of neuroblastoma cells show that HO-1 expression is coordinated with phosphorylation suggesting a physiologic interaction between cytoskeleton reorganization and oxidation. <ref type="bibr" target="#b44">45</ref> In consideration of the enzymatic activity of HO-1 to produce iron and to bind iron, <ref type="bibr" target="#b45">46</ref> the coordination may relate to iron homeostasis. These results clearly implicate a regulated process for modifications and responses. Changes such as HO-1 and MAP kinase pathway induction may be only a few of many responses that interrelate to lipid peroxidative modifications. In this way, oxidative damage is no longer an end stage but rather a signal of underlying changes of state.</p><p>Furthermore, an antioxidant role for A␤ in vivo is in agreement with recent data on the distribution of oxidative damage to AD neurons. 8OHG, a major product of nucleic acid oxidation, markedly accumu-</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 1. Possible sequence of neuronal events that occurs in Alzheimer disease (AD). In the initial stages of AD, the increase in oxidative stress levels, mainly promoted by the interplay between the reactive species formed by mitochondria and the transition metals, induce neuronal compensatory responses and downstream adaptations, such as MAP kinase activation, A␤ deposition and hyperphosphorylation, aimed to avoid neuronal damage and/or</head><p>death. However, with the progression of AD and the consequent increase of reactive species levels, the efficient removal of A␤-metal complexes and, probably, hyperphosphorylated would be overtaken by their disproportionably high generation, resulting in and uncontrollable growth of plaques and NFT. These responses are associated with a reduction in normal cell function resulting, inevitably, in neuronal damage and death.</p><p>lates in the cytoplasm of cerebral neurons in AD. Unexpectedly, an increase in A␤ deposition in AD cortex is associated with a decrease in neuronal level of 8OHG, such as with decreased oxidative damage. <ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b46">47</ref> Similar negative correlation between A␤ deposition and oxidative damage is found in patients with Down syndrome. <ref type="bibr" target="#b47">48</ref> A␤ deposits observed in both studies mainly consist of early diffuse plaques meaning that these diffuse amyloid plaques may be considered as a compensatory response that reduces oxidative stress. <ref type="bibr" target="#b48">49</ref> The protective properties of A␤ could be related with its capacity to scavenge free radicals and the chelation of transition metals. <ref type="bibr" target="#b49">50,</ref><ref type="bibr" target="#b50">51</ref> Altogether these findings suggest that both A␤ and NFT, in the initial stages of AD development, may be compensations to increased oxidative stress and might play a similar role in s-IBM.</p><p>Therapeutic strategies. Given the proximal role and devastating effect that oxidative stress plays in AD pathogenesis, a therapeutic strategy based on fighting oxidative stress appears reasonable. Certainly, such an assumption should be considered more reasonable than strategies based either on removal of A␤ or on preventing the phosphorylation of it, because both represent downstream consequences of oxidative stress and/or a concerted cellular effort to maintain homeostatic balance. In addition, data from the literature show that strategies envisaging the removal of A␤ deposits (immunotherapy) have severe side effects such as the activation of CNS inflammatory responses <ref type="bibr" target="#b51">52,</ref><ref type="bibr" target="#b52">53</ref> as well as possible consequences of removal of A␤ from the brain. <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b53">54</ref> There is overwhelming clinical evidence that antioxidants, free-radical fighters, slow the symptoms of both dementia and AD. Although modest, several epidemiologic studies have shown lower risks of dementia and AD progression in people taking dietary antioxidants. <ref type="bibr" target="#b54">55</ref> However, the broad occurrence of AD (almost 50% by the age of 85), the nonregenerative nature of the CNS and the fact that diagnosis often does not occur until late in disease progression, suggest that the ideal antioxidant should be used as prophylactic treatment in aged population. Due to their low toxicity, low cost and their ability to target the earliest sources of oxidative stress in AD, antioxidant therapies are particularly attractive. Could antioxidants have therapeutic utility in s-IBM?</p><p>Conclusions. Oxidative stress is not the breach of antioxidant defenses for chronic conditions, pathologic and physiologic, and that a better understanding occurs by viewing each circumstance as a different homeostatic balance in which reactive oxygen and nitrogen species play a key regulatory role. In the initial stages of AD development, neuronal cells despite showing increased oxidative damage may actually be in homeostatic balance. If cells survive and function in the presence of high levels of oxidative stress, it is because critical systems of cells are not damaged. In this way, detection of increased oxidative damage, in cells that survive, must be associated with a commensurate increase in compensatory mechanisms such as A␤ deposition and hyperphosphorylated . However, with the progression of AD and the consequent increase of reactive species levels, the efficient removal of A␤-metal complexes and, probably, hyperphosphorylated would be overtaken by their disproportionably high generation, resulting in an uncontrollable growth of senile plaques and NFT and consequently, an increase in reactive species generation. This would result in a feedback mechanism that could exacerbate plaque and NFT growth and reactive species generation, leading to a functional demise of neurons (figure <ref type="figure">1</ref>).</p><p>Muscle cells in s-IBM show many of the same changes documented in AD (figure <ref type="figure" target="#fig_0">2</ref>) and it would seem likely that similar mechanisms are involved. Neurons and muscle share high metabolic activity and are postmitotic. A highly developed cytoskeleton is essential to both, for movement in muscle and transport in neurons. Understanding and dissecting these commonalities that lead to similar pathophysiology will result in a better mechanistic appreciation of s-IBM and AD. <ref type="bibr" target="#b55">56</ref>  </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 2 .</head><label>2</label><figDesc>Figure 2. Similar pathologic changes define vulnerable neurons in AD and muscle cells in s-IBM. They share almost every feature.</figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0">S98 NEUROLOGY 66(Suppl 1) January 2006</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1">January 2006 NEUROLOGY 66(Suppl 1) S99</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_2">January 2006 NEUROLOGY 66(Suppl 1) S101</note>
		</body>
		<back>

			<div type="funding">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Supported by the National Institues of Health, the Alzheimer's Association,</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Treatment of Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mayeux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">341</biblScope>
			<biblScope unit="page" from="1670" to="1679" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Creutzfeldt-Jakob disease and inclusion body myositis: abundant disease-associated prion protein in muscle</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Kovacs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lindeck-Pozza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chimelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="121" to="125" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Increased expression of the normal cellular isoform of prion protein in inclusion-body myositis, inflammatory myopathies and denervation atrophy</title>
		<author>
			<persName><forename type="first">G</forename><surname>Zanusso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ferrari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Pathol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="182" to="189" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Alzheimer&apos;s disease and prion proteins: a meeting made in muscle</title>
		<author>
			<persName><forename type="first">P</forename><surname>Gambetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="1261" to="1264" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Novel immunolocalization of alpha-synuclein in human muscle of inclusionbody myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Broccolini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="592" to="598" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Aging: a theory based on free radical and radiation chemistry</title>
		<author>
			<persName><forename type="first">D</forename><surname>Harman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gerontol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="298" to="300" />
			<date type="published" when="1956">1956</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Do neurons have a choice in death?</title>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Apoptosis and Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nunomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lucassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lassmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">282</biblScope>
			<biblScope unit="page" from="1268" to="1269" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">A suicide note from Alzheimer disease neurons</title>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nunomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="897" to="898" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Iron accumulation in Alzheimer disease is a source of redox-generated free radicals</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Sayre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="9866" to="9868" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Widespread peroxynitrite-mediated damage in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Richeyharris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Sayre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Beckman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="2653" to="2657" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Richey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Taneda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann NY Acad Sci</title>
		<imprint>
			<biblScope unit="volume">738</biblScope>
			<biblScope unit="page" from="447" to="454" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Montine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Amarnath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Strittmatter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Graham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="89" to="93" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Sayre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Zelasko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Salomon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="2092" to="2097" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Radical AGEing in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Sayre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Monnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Neurosci</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="172" to="176" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Castellani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Sayre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Free Radic Biol Med</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="175" to="180" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Advanced Maillard reaction end products are associated with Alzheimer disease pathology</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Taneda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Richey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="5710" to="5714" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response</title>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Taddeo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nunomura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Comp Biochem Physiol C Toxicol Pharmacol</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="507" to="513" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The glucose transporter of the human brain and blood-brain barrier</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Kalaria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Gravina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Schmidley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Harik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="757" to="764" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Mitochondrial abnormalities in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hirai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Aliev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nunomura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="3017" to="3023" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Mitochondrial diseases in man and mouse</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Wallace</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">283</biblScope>
			<biblScope unit="page" from="1482" to="1488" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Oxidative stress signalling in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Raina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Casadesus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res</title>
		<imprint>
			<biblScope unit="volume">1000</biblScope>
			<biblScope unit="page" from="32" to="39" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Role of mitochondrial dysfunction in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">R</forename><surname>Castellani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hirai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Aliev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci Res</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="357" to="360" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Mitochondrial DNA variants in inclusion body myositis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Kok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Boyt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gaudieri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuromuscul Disord</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="604" to="611" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy</title>
		<author>
			<persName><forename type="first">R</forename><surname>Lodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Tabrizi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="2119" to="2126" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Pleomorphic mitochondrial and different filamentous inclusions in inflammatory myopathies associated with mtDNA deletions</title>
		<author>
			<persName><forename type="first">M</forename><surname>Molnar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Schroder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="41" to="51" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Characterization of the mitochondrial DNA abnormalities in the skeletal muscle of patients with inclusion body myositis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Horvath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Johns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Genge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Shoubridge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="396" to="403" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Microtubule reduction in Alzheimer&apos;s disease and aging is independent of tau filament formation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Cash</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Aliev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Siedlak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="1623" to="1627" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Premkumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Richey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1399" to="1402" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Alzheimer&apos;s disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification</title>
		<author>
			<persName><forename type="first">A</forename><surname>Takeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Avila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="1234" to="1241" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Heme catabolism and heme oxygenase in neurodegenerative disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Takeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Itoyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kimpara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antioxid Redox Signal</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="888" to="894" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Keyse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Tyrrell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="99" to="103" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Oxidative stress and redox-active iron in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">K</forename><surname>Honda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Casadesus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann NY Acad Sci</title>
		<imprint>
			<biblScope unit="volume">1012</biblScope>
			<biblScope unit="page" from="179" to="182" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nunomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Pappolla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1959" to="1964" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Oxidative damage is the earliest event in Alzheimer disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nunomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Aliev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="759" to="767" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Neuronal RNA oxidation is a prominent feature of familial Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nunomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chiba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Lippa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurobiol Dis</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="108" to="113" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Paired helical filaments from Alzheimer disease patients contain cytoskeletal components</title>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rizzuto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Autilio-Gambetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gambetti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="3916" to="3920" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal</title>
		<author>
			<persName><forename type="first">T</forename><surname>Wataya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nunomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page" from="4644" to="4648" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Tau modifiers as therapeutic targets for Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Honda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochim Biophys Acta</title>
		<imprint>
			<biblScope unit="volume">1739</biblScope>
			<biblScope unit="page" from="211" to="215" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal</title>
		<author>
			<persName><forename type="first">M</forename><surname>Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cuadros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Avila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">486</biblScope>
			<biblScope unit="page" from="270" to="274" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Formation of aberrant phosphotau fibrillar polymers in neural cultured cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gomez-Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Avila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Biochem</title>
		<imprint>
			<biblScope unit="volume">269</biblScope>
			<biblScope unit="page" from="1484" to="1489" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation</title>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Roder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nunomura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="2411" to="2415" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Activation of MKK6, an upstream activator of p38, in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Rottkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hartzler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="311" to="318" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Raina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Rottkamp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="435" to="441" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau</title>
		<author>
			<persName><forename type="first">A</forename><surname>Takeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Abraham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">275</biblScope>
			<biblScope unit="page" from="5395" to="5399" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer&apos;s disease: a central role for bound transition metals</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Sayre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Schubert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="270" to="279" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Neuronal RNA oxidation in Alzheimer&apos;s disease and Down&apos;s syndrome</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nunomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hirai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann NY Acad Sci</title>
		<imprint>
			<biblScope unit="volume">893</biblScope>
			<biblScope unit="page" from="362" to="364" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nunomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Pappolla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="1011" to="1017" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Tracking the culprit in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Joseph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Perry</forename><forename type="middle">G</forename><surname>Arson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann NY Acad Sci</title>
		<imprint>
			<biblScope unit="volume">924</biblScope>
			<biblScope unit="page" from="35" to="38" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Copper, iron and zinc in Alzheimer&apos;s disease senile plaques</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Lovell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Robertson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Teesdale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Markesbery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Sci</title>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="page" from="47" to="52" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Antiinflammatory activity of methionine, methionine sulfoxide and methionine sulfone</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Unnikrishnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Rao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Agents Actions</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="110" to="112" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Immunotherapeutic approaches to Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Monsonego</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Weiner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">302</biblScope>
			<biblScope unit="page" from="834" to="838" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Nicoll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wilkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Holmes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Steart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Markham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Weller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="448" to="452" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Amyloid-beta junkies</title>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nunomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Raina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="page">757</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Current concepts in the prevention of Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CNS Spectr</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="846" to="853" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Newest pathogenetic considerations in inclusion-body myositis: possible role of amyloid-beta, cholesterol, relation to aging and to Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Rheumatol Rep</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="427" to="433" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
